Answers are grounded in this paper and cite their sources.
Rituximab-induced serum sickness (RISS) is a rare complication of Rituximab (RTX) in immunobullous disorders. Clinicians should be aware of the occurrence of serum sickness symptoms during RTX administration, and prompt initiation of corticosteroid therapy is crucial in these patients. Additionally, RISS may occur with subsequent RTX doses and patients should be counseled accordingly.
No takes yet. Share an insight, caveat, or question.
Gheisari et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: